Simultaneous activation of glucagon, GIP, and GLP-1 by efocipegtrutide (HM15211) could provide improved anti-inflammatory and anti-fibrotic effects in thioacetamide-induced mouse model of livery injury and fibrosis
Serum metabolomic, lipidomic and proteomic profiling identifies new biomarkers associated with the treatment of denifanstat, a fatty acid synthase inhibitor, in NASH patients
DENIFANSTAT (DEN), A FIRST IN CLASS FATTY ACID SYNTHASE (FASN) INHIBITOR, SIGNIFICANTLY REDUCES PLASMA TRIPALMITIN, A MARKER OF DE NOVO LIPOGENESIS, IN NASH PATIENTS IN THE FASCINATE 1 AND FASCINATE 2 CLINICAL STUDIES
Pegozafermin Led to Significant Metabolic Benefits, in Addition to Robust Beneficial Effects on the Liver, in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis (NASH)
Prevalence of esophageal and gastric varices in patients with compensated non alcoholic steatohepatitis (NASH) cirrhosis and portal hypertension. Data from the NAVIGATE study
Combination of noninvasive prognostic biomarkers, corrected T1 and enhanced liver fibrosis test, for the enrichment of at-risk nonalcoholic steatohepatitis or advanced fibrosis
Introduction of NAFLD/NASH genetic risk factors PNPLA3-I148M and TM6SF2-E167K in HepaRG cells reveals distinct metabolic profiles in high-throughput organ-on-a-chip system.
EFFICACY, SAFETY, AND TOLERABILITY OF CONTINUED LPCN 1144 TREATMENT IN NONALCOHOLIC STEATOHEPATITIS (NASH) SUBJECTS WITH FIBROSIS IN AN OPEN LABEL EXTENSION STUDY
Focused monitoring and management guidance reduces the incidence of hepatic safety events: Results from the phase 3 REGENERATE trial of obeticholic acid for nonalcoholic steatohepatitis
